Compared to CP, starting screening at 25 years with primary HPV testing (strategy sub-groups a and b) was predicted to be associated with a higher cancer incidence rate in 25–29 year-old women (the first 5 years after screening begins) but a significantly lower rate in 30+ years (Fig 2). The gene discussed is CP; the disease is cancer.